Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 19, 2026
Genelux Corporation (GNLX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$8.0 million. As of Jun 30, 2026 it held $18.7 million in cash and investments and $2.4 million in total debt.
Revenue
$0
Net income
$-9.47M
-27.0% vs year-ago quarter
Operating cash flow
$-6.44M
+8.7% vs year-ago quarter
Free cash flow
$-7.98M
-11.2% vs year-ago quarter
EPS
$-0.21
-5.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
45.25M
+19.8% vs year-ago quarter
Net cash
$16.26M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GNLX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westlake Village, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1231457
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | — | — |
| Operating income | -$9.6M | -$9.2M | -$9.4M | -$8.2M | -$7.8M |
| Net income | -$9.5M | -$8.9M | -$9.2M | -$8.0M | -$7.5M |
| Diluted EPS | -$0.21 | -$0.20 | -$0.24 | -$0.21 | -$0.20 |
| Operating cash flow | -$6.4M | -$6.1M | -$6.2M | -$6.6M | -$7.1M |
| Free cash flow | -$8.0M | -$7.0M | -$6.6M | -$7.1M | -$7.2M |
| Total assets | $26.2M | $32.4M | $19.0M | $25.0M | $32.2M |
| Total liabilities | $10.1M | $9.5M | $7.5M | $6.4M | $8.3M |
| Stockholders' equity | $16.1M | $22.9M | $11.5M | $18.6M | $23.9M |
| Cash and investments | $18.7M | $26.2M | $14.6M | $16.2M | $28.0M |
| Total debt | $2.4M | $2.5M | $1.7M | $1.6M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 19, 2026 | Mar 19, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
All 362 Genelux Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.